Cargando…

Escalation vs. Early Intense Therapy in Multiple Sclerosis

The treatment strategy of multiple sclerosis (MS) is a highly controversial debate. Currently, there are up to 19 drugs approved. However, there is no clear evidence to guide fundamental decisions such as what treatment should be chosen in first place, when treatment failure or suboptimal response s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casanova, Bonaventura, Quintanilla-Bordás, Carlos, Gascón, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778390/ https://www.ncbi.nlm.nih.gov/pubmed/35055434 http://dx.doi.org/10.3390/jpm12010119

Ejemplares similares

Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain
por: Landete, Lamberto, et al.
Publicado: (2021)

Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series
por: Quintanilla-Bordás, Carlos, et al.
Publicado: (2022)

Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis
por: Alcalá Vicente, Carmen, et al.
Publicado: (2022)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Gascón-Giménez, Francisco, et al.
Publicado: (2023)

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
por: Iaffaldano, Pietro, et al.
Publicado: (2021)

Potential Biomarkers Associated with Multiple Sclerosis Pathology
por: Mathur, Deepali, et al.
Publicado: (2021)

Switching and Escalating Therapy in Long-Lasting Multiple Sclerosis: Not Always Necessary
por: Carvalho, Ana Teresa, et al.
Publicado: (2012)

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
por: Casanova, Bonaventura, et al.
Publicado: (2017)

High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis
por: Castillo-Villalba, Jéssica, et al.
Publicado: (2022)

Perturbed Glucose Metabolism: Insights into Multiple Sclerosis Pathogenesis
por: Mathur, Deepali, et al.
Publicado: (2014)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Functional and structural changes in the visual pathway in multiple sclerosis
por: Carcelén‐Gadea, María, et al.
Publicado: (2019)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Iranian specialists’ approach to treatment escalation in multiple sclerosis patients with cognitive impairment
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

De-Escalation of Therapy for Patients with Early-Stage Squamous Cell Carcinoma of the Anus
por: Miller, Eric, et al.
Publicado: (2021)

Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis
por: Gil-Perotin, Sara, et al.
Publicado: (2019)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
por: Johnson, Kenneth P
Publicado: (2010)

Bypassing hazard of housekeeping genes: their evaluation in rat granule neurons treated with cerebrospinal fluid of multiple sclerosis subjects
por: Mathur, Deepali, et al.
Publicado: (2015)

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer
por: Gianni, Caterina, et al.
Publicado: (2022)

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
por: Vollmer, Brandi L., et al.
Publicado: (2022)

Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: safety algorithm()
por: Valero-López, G., et al.
Publicado: (2020)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis
por: Edo Solsona, María Dolores, et al.
Publicado: (2017)

Neurodegeneration in Multiple Sclerosis: The Role of Nrf2-Dependent Pathways
por: Maldonado, Paloma P., et al.
Publicado: (2022)

Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice
por: Gragnano, Felice, et al.
Publicado: (2022)

Radiobiological evaluation of simultaneously dose-escalated versus non-escalated intensity-modulated radiation therapy for patients with upper thoracic esophageal cancer
por: Huang, Bao-Tian, et al.
Publicado: (2017)

Newer therapies for multiple sclerosis
por: Coles, Alasdair
Publicado: (2015)

Optic neuritis as an early sign of multiple sclerosis
por: Kale, Nilufer
Publicado: (2016)

Emerging therapies for treatment of multiple sclerosis
por: Corboy, John R, et al.
Publicado: (2010)

Current concepts in multiple sclerosis therapy
por: Sedal, Leslie, et al.
Publicado: (2017)

That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
por: Davis, Matthew R., et al.
Publicado: (2020)

Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects
por: Mathur, Deepali, et al.
Publicado: (2017)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
por: Edan, Gilles, et al.
Publicado: (2023)

INTENSIVE CIRCUIT CLASS THERAPY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
por: KOCICA, Jan, et al.
Publicado: (2022)

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
por: Wiendl, Heinz, et al.
Publicado: (2021)

Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia
por: Joung, Mi Kyong, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h8an910d11lmvohisc6odc6bem